Press Releases

Ben Seon, PhD
News

Immunotherapy-Chemo Combo Based on Work of Roswell Park’s Dr. Ben Seon Gets FDA Approval

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration (FDA) for patients with an aggressive form of non-Hodgkin lymphoma. On June 10, the FDA granted accelerated approval to polatuzumab vedotin as part of a new chemotherapy/immunotherapy treatment combination for patients with relapsed or refractory diffuse large B-cell lymphoma.
News

National Cancer Institute Renews Roswell Park’s Prestigious ‘Comprehensive’ Designation

The National Cancer Institute (NCI) has affirmed its support for Roswell Park Comprehensive Cancer Center, renewing its status as one of 50 elite Comprehensive Cancer Centers and awarding a $22.5 million Cancer Center Support Grant (CCSG) to fund core research and education programs — the largest such award and highest application score in Roswell Park’s history. Roswell Park has held this prestigious NCI designation continuously since it became one of the nation’s very first Comprehensive Cancer Centers more than 45 years ago.
News

Tumor Expression Pattern May Predict Recurrence in Non-Small Cell Lung Cancer

Roswell Park Comprehensive Cancer Center physicians Grace Dy, MD, Chief of Thoracic Oncology, and Maya Khalil, MD, Chief Hematology-Oncology Fellow​, led an effort to identify whether the tumor microenvironment can predict risk of disease recurrence in patients with non-metastatic lung adenocarcinoma. Dr. Khalil will present the team’s findings this week at the 55th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.